Nixol introduces a new natural supplement in the United Kingdom to support metabolism, curb cravings, and promote healthy ...

Dr. Mac Sweeney’s theory is now attracting attention from experts in evolutionary biology, bioengineering, and anatomical ...

The clinic performs more than 2000 implant procedures each year across its locations, highlighting the sustained demand for ...

Total Orthopedics and Sports Medicine, a leading multi-specialty orthopedic practice with 14 locations across the region, ...

Multipronged approach to overcome the challenge of anti-drug antibodies to serve as the foundation of new subsidiary, AdaMunix ...

Known for its commitment to natural legal steroids and high-performance muscle building supplements, CrazyBulk is fast ...

The trial results demonstrated a favorable safety and tolerability profile consistent with GLP-1-based treatments and previously reported HRS9531 Phase 2 clinical data. Most treatment-emergent adverse ...

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of July 2025, which is payable on ...

Newly issued U.S. patent extends certepetide IP protection to 2040, with subsequent opportunity for patent term extension BASKING RIDGE, N.J, July 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc ...

PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, compared to current standard of care of ...

BriaCell’s pivotal Phase 3 clinical study is evaluating BriaCell’s lead clinical candidate, Bria-IMT™, plus immune check point inhibitor (CPI) versus physician’s choice in a dvanced metastatic b reast ...

- Abeona Therapeutics® and Stanford Medicine conducted research collaboration for more than a decade, culminating in U.S. Food and Drug Administration (FDA) approval of ZEVASKYN in April 2025 - ...